| Ariadne (psychedelic) | |
|---|---|
|
1-(2,5-Dimethoxy-4-methyl-benzyl)-propylamine |
|
|
Other names
4-Methyl-2,5-dimethoxy-alpha-ethylphenethylamine |
|
| Identifiers | |
| CAS number | 52842-59-8 |
| PubChem | 169886 |
| ChemSpider | 148565 |
| Jmol-3D images | Image 1 Image 2 |
|
|
|
|
| Properties | |
| Molecular formula | C13H21NO2 |
| Molar mass | 223.31 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
Ariadne (Dimoxamine, α-Et-DOM), or 4-methyl-2,5-dimethoxy-alpha-ethylphenethylamine, is a lesser-known psychedelic drug. It is a homologue of 2C-D and DOM. Ariadne was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin reported testing Ariadne up to a dose of 32 mg, and reported that it produces psychedelia and a bare threshold.[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of Ariadne in humans apart from Shulgin's limited testing.
However, in more recent animal studies, α-Et-DOM was shown to produce stimulus generalisation in rats trained to respond to the drug MDMA.[2] This suggests that while α-Et-DOM may lack hallucinogenic effects, it might potentially produce empathogenic effects similar to those of MDMA if used at higher dose ranges, beyond those trialled by Shulgin (the potency of α-Et-DOM in this study was similar to that of MDMA, 1.5 mg/kg, which would equate to a dose of ~100 mg in a human).
|
||||||||||||||
| This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)